Who are Clarithromycin DST (187.5 mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zmax, Clindamycin Gel (clindamycin ), Azithropycin according to symptoms, IV azithromycin, Topical Clindamycin, Dalacin C.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clarithromycin-dst-187-5-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Clarithromycin DST (187.5 mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clarithromycin DST (187.5 mg) (Clarithromycin DST (187.5 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease.

phase 3 Macrolide antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Clarithromycin DST (187.5 mg) (Clarithromycin DST (187.5 mg)) — Grünenthal GmbH. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clarithromycin DST (187.5 mg) TARGET	Clarithromycin DST (187.5 mg)	Grünenthal GmbH	phase 3	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Zmax	Zmax	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Clindamycin Gel (clindamycin )	Clindamycin Gel (clindamycin )	Stiefel, a GSK Company	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
IV azithromycin	IV azithromycin	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Topical Clindamycin	Topical Clindamycin	University of Toronto	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Dalacin C	Dalacin C	Oral and Maxillofacial Surgery Clinic, Poland	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

Pfizer · 6 drugs in this class
Grünenthal GmbH · 4 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
University of Taubate · 2 drugs in this class
Lihir Medical Centre · 2 drugs in this class
Thomas Jefferson University · 2 drugs in this class
Copenhagen Studies on Asthma in Childhood · 1 drug in this class
Ain Shams Maternity Hospital · 1 drug in this class
Celltrion · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clarithromycin DST (187.5 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/clarithromycin-dst-187-5-mg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab